Curcumin and pancreatic cancer: Phase II clinical trial experience

• Published in: Journal of clinical oncology Vol. 25; no. 18_suppl; p. 4599
• Main Authors: Dhillon, N., Aggarwal, B. B., Newman, R. A., Wolff, R. A., Kunnumakkara, A. B., Abbruzzese, J. L., Hong, D. S., Camacho, L. H., Ng, C., Kurzrock, R.
• Format: Journal Article
• Language: English
• Published: 20.06.2007

Abstract only 4599 Background: Pancreatic cancer is virtually always lethal, and the only FDA-approved therapies–gemcitabine and erlotinib–produce objective responses in less than 10% of patients. Curcumin (diferuloyl methane) is a plant-derived dietary ingredient that suppresses NF-κB and numerous...